HEATHER Feedback Meeting

Slides:



Advertisements
Similar presentations
Effect of intensification of long-term highly active antiretroviral therapy (HAART) with raltegravir on proviral HIV-1 DNA in blood and gut associated.
Advertisements

Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.
New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.
Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
Measuring the latent HIV Reservoir
Unique integration patterns in an in vitro model of HIV-1 latency. Suha M. Saleh, Dimitrios Vatakis, Andrew Harman, Anthony Cunningham, Paul U. Cameron,
Contribution of the immune system to HIV persistence Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine,
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
Main questions on HIV persistence and on obstacles to HIV eradication Jean-Pierre Routy M.D. McGill University Montreal Toward an HIV cure: Insight into.
HIV 101 Review Evaluation Center for HIV and Oral Health Boston University School of Public Health Health & Disability Working Group.
Instructions To use this template: –for each slide write the correct answer on the orange bar first –choose which option (A,B,C or D) and make sure you.
1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8):
Marian Kerbleski, RN UCSF AIDS Division San Francisco General Hospital.
EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.
Strategies for Targeting and Eradicating the HIV Reservoir
David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.
2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
The role of PI3K signaling pathways in HIV-1 infection of resting CD4+T-cells Suha Saleh, Paul Cameron, Georgina Sallmann, Anthony Jaworowski, and Sharon.
Future directions in HIV basic science research The hunt for a cure.
HIV Cellular Pathogenesis III
Future directions in HIV basic science research The hunt for a cure.
Characterization of persistent HIV-1 in a broad spectrum of CD4 + T-cells isolated from peripheral blood, bone marrow, lymphoid tissue and gut associated.
Viral Tissue Reservoirs Are Determined Early and Little Viral RNA Is Detected during Suppression in the Macaque Model Zandrea Ambrose, Ph.D. Division of.
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
Learning About an HIV Cure by Doing Studies in HIV+ Subjects Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University.
Myeloid dendritic cells induce HIV-1 latency in non- proliferating CD4 + T cells IAS WORKSHOP, 16 & 17 JULY 2010.
Future directions in HIV basic science research The hunt for a cure.
T-CELL MEMORY Central Effector. 1781:Measles epidemic in the Faroe Islands No measles for 65 years 1846: Measles epidemic Those individuals, who were.
HIV pathogenesis The course of HIV infection 1. Acute Phase 2. Intermediate (asymptomatic) phase -viral load stabilizes at a “set point”. 3. Late (symptomatic)
HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.
The Future of HIV/AIDS: The Road to a Cure. How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun,
Immune reconstitution Anjie Zhen, PhD
2014 “Towards an HIV Cure” symposium Melbourne An Overview of HIV Cure Research in 2014 Diana Finzi, Ph.D. Director, Basic Science Program Division of.
Diseases. Variations  Disease- a disorder of a body, system, organ structure or function. Ex. Christmas Disease (hemophilia B)  Virus- any member of.
Viruses. Classifying Viruses How to tell them apart.
Davey Smith, MD Professor of Medicine University of California San Diego La Jolla, California When Will It All Be Over? HIV Cure Efforts Los Angeles, California:
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK
State of HIV Cure Research
No Evidence Of Ongoing Replication In Tissue Compartments During cART
HIV Cure: Current Status and Future Perspectives
What’s Your Health IQ? True or False
Latent Infection In the nonimmune (susceptible) host, the bacilli initially multiply unopposed by normal host defense mechanisms. The organisms are then.
Feedback meeting September 2017
UK CAB HIV Cure meeting 3rd August 2018
Human Health and Disease
Hiv.
Didier Trono, Flavia Marzetta  Cell Host & Microbe 
Figure 2 Systemic immune responses to cryptococcal antigen
The block-and-lock approach
Follicular CD8+ T-cells (fCD8) in GALT are associated with lower HIV-1 reservoir in the terminal ileum after ART initiated during PHI John Thornhill Imperial.
Why we should ‘shock and kill’
Nat. Rev. Neurol. doi: /nrneurol
O. Turriziani, M. Andreoni, G. Antonelli 
The Expression Pattern of Epstein-Barr Virus Latent Genes In Vivo Is Dependent upon the Differentiation Stage of the Infected B Cell  Gregory J Babcock,
EBV infection in healthy carriers.
Robyn S. Klein, Christopher A. Hunter  Immunity 
Double Trouble: HIV Latency and CTL Escape
Skin-Resident T Cells: The Ups and Downs of On Site Immunity
Alex Sigal, David Baltimore  Cell Host & Microbe 
An Integrated Overview of HIV-1 Latency
Steven Yukl UCSF and San Francisco VA
Celiac disease as a model for SLE
The Dispersal of Mucosal Memory B Cells
Replication and intercellular transmission of HIV-1 is increased during antigen presentation. Replication and intercellular transmission of HIV-1 is increased.
Mayibongwe L. Mzingwane, PhD Department of Pathology
Immunologic strategies for HIV-1 remission and eradication
Presentation transcript:

HEATHER Feedback Meeting John Thornhill

Sanctuary Sites

Barriers to HIV cure: Tissue reservoirs HIV infects CD4+ cells Dormant memory T cells in lymph nodes and blood2 Various tissues (especially in lymph nodes and gut Major reservoirs Some become resting cells; ‘reservoir’ Most CD4+ T cells infected with HIV die due to the effects of the virus; however, a small sub-set of so-called ‘resting’ memory T cells that harbour the virus persist indefinitely – this is known as latent infection1 Latent HIV infection may also occur in cell populations other than memory CD4+ T cells, including naive CD4+ T cells, tissue macrophages, astrocytes, thymocytes and perhaps haematopoietic progenitor cells2-6 In essence, latency can be defined as ‘the maintenance in the host genome of integrated viral DNA that is replication-competent but transcriptionally silent’1 The inability of the immune system to recognise cells harbouring latent virus and to eliminate cells actively producing virus is the biggest challenge to cure treatments The HIV reservoir is established during primary infection. Early treatment can reduce the total size of the reservoir; however, a stable population of latently infected CD4 cells transits into the long-lived latent reservoir, and is unaffected by early combination ART (cART)1. Cellular reservoirs7: In addition to the CD4+ T cells reservoir in the lymph nodes, there are different cellular reservoirs for different anatomical reservoirs eg. microglia in the CNS. Anatomical reservoirs7,8 GALT is one of the major anatomical reservoirs The lymph nodes, CNS and the blood are also important anatomical reservoirs of latent virus References Deeks SG, et al. Nat Rev Immunol 2012;12(8):607–14. Stebbing J, et al. N Engl J Med 2004;350(18):1872–80. Wightman F, et al. J Infect Dis 2010;202:1738–48. Kitchen SG, Zack JA. J Virol 1997;71:6928–34. Carter CC, et al. Nature Med 2010;16:446–51. Churchill MJ, et al. Ann Neurol 2009;66(2):253–58. Alexaki A, et al. Curr HIV Res 2008;6(5):388–400. Yukl SA, et al. J Infect Dis 2010;202(10):1553–61 Created from Coiras M, et al. Nat Med 2009;7:798–812. 1. Rouzioux C, et al. JID 2005;192:46-55. 2. Deeks SG, et al. Nat Rev Immunol 2012;12(8):607–14

HEATHER gut sub-study Started enrolling in May 2016 20 individuals enrolled 5 people have had 2 biopsies (1 year apart) Aims to look at the Reservoir in the gut How large is it Where is it in the gut Are certain cells more important than others Closed to recruitment

The Size of the Reservoir

The HIV reservoir still very rare Other markers of HIV and the reservoir are important Some of the markers have drugs which target them

Markers than indicate the presence of a reservoir or infected cell are found more often in the gut New Drugs can target some of these flags or markers Might be important for eliminated the reservoir in sanctuary sites like the gut Some of these drugs have side effects and may not be suitable for PLWH HIV CD4 Cell Level of PD-1 is x5 times higher in the gut

Future Work Complete all the biopsies for the HEATHER study See if the reservoir is stable over time Do these markers reflect the reservoir in the gut Look at the gut reservoir in people who have received drugs aimed to reduce the reservoir